March 23rd 2024, 5:00pm
As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the issues faced by adolescent and young adult patients with cancer as they age into adult care.
As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about how a cancer diagnosis ‘adds a new identity’ for adolescent and young adult patients.
As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the power of mindfulness practices such as yoga and meditation.
As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the current landscape of research for adolescent and young adult patients with cancer.
March 21st 2024, 1:00pm
A new robot-assisted nipple-conserving mastectomy is “not very different” in terms of patient experiences versus the traditional procedure.
March 20th 2024, 10:00pm
In collaboration with the Kidney Cancer Association, CURE® recently hosted the “Educated Patient® Webinar: Treating the Whole Patient: Navigating Kidney Cancer,” hosted by Darlene Dobkowski, Associate Editorial Director for CURE®.
March 13th 2024, 10:00pm
As part of its Speaking Out video series, CURE® spoke with Lisa Carter-Bawa of Hackensack Meridian Health about the role nurses play in helping patients manage treatment side effects.
As part of its Speaking Out video series, CURE® spoke with Upal Basu Roy of LUNGevity about recently approved treatments for lung cancer and what is on the horizon.
As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of LUNGevity about the chemotherapy shortage and its impact on patients with lung cancer.
As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of Lungevity about advancements in treatments for small cell lung cancer.
Ojemda Preserves Quality of Life, Limits Cognitive Effects in Low-Grade Glioma
Most BCG-Unresponsive Bladder Cancer Responds to TAR-200 Treatment
The Hard Truth About My Child’s Cancer
FDA to Review Injectable Opdivo for All Approved Indications